arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2017-23-2-160-171arthyper-590Research ArticleСтатьиArticlesКОНЦЕПЦИЯ СОСУДИСТОГО ВОЗРАСТА: НОВЫЙ ИНСТРУМЕНТ ОЦЕНКИ СЕРДЕЧНО-СОСУДИСТОГО РИСКАCONCEPT OF VASCULAR AGE: NEW TOOL IN CARDIOVASCULAR RISK ASSESSMENTТроицкаяЕ. А.TroitskayaE. A.

кандидат медицинских наук, ассистент кафедры внутренних болезней с курсом кардиологии и функциональной диагностики

PhD, Assistant of the Professor, Department of the Internal Diseases with Cardiology and Functional Diagnostics

troitskaya_ea@rudn.universityВельмакинС. В.VelmakinS. V.

ассистент кафедры внутренних болезней с курсом кардиологии и функциональной диагностики Медицинского института

Assistant of the Professor, Department of the Internal Diseases with Cardiology and Functional Diagnostics

troitskaya_ea@rudn.universityКобалаваЖ. Д.KobalavaZ. D.

доктор медицинских наук, профессор, заведующая кафедрой внутренних болезней с курсом кардиологии и функциональной диагностики Медицинского института

MD, PhD, Professor, Head, Department of the Internal Diseases with Cardiology and Functional Diagnostics

troitskaya_ea@rudn.universityФедеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов» Министерства образования и науки Российской Федерации, МоскваРоссияRUDN University, MoscowRussian Federation201715052017232160171Copyright © Троицкая Е.А., Вельмакин С.В., Кобалава Ж.Д., 20172017Троицкая Е.А., Вельмакин С.В., Кобалава Ж.Д.Troitskaya E.A., Velmakin S.V., Kobalava Z.D.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/590

Возрастающий интерес к проблемам сосудистого старения и поиску новых доступных параметров, отражающих влияние данного процесса на сердечно-сосудистый риск, привели к появлению показателя «сосудистый возраст», представляющего собой способ выражения риска сердечно-сосудистых осложнений в виде возраста. Легкость в восприятии данного параметра позволяет улучшить коммуникацию между врачом и пациентом и понимание пациентом своего состояния, что способствует повышению приверженности к лечению. Кроме того, показатель сосудистого возраста может служить инструментом для переоценки категории сердечно-сосудистого риска. В обзоре суммированы основные данные, на которых основано современное представление о сосудистом возрасте: определение, методы расчета, клиническое значение и возможности терапии.

 

Increasing interest to the problems of vascular ageing and need in novel parameters reflecting impact of this process on cardiovascular risk have led to the development of a concept of vascular age. Vascular age reflects cardiovascular risk. It is thought to improve cardiovascular risk prediction models and may contribute to a better understanding of cardiovascular risk, especially in young patients. The review summarizes the current knowledge on the definition, assessment and clinical significance of vascular age.

 

сосудистый возрастсердечно-сосудистый рисксосудистое старениеvascular agecardiovascular riskvascular ageingReferencesWorld Health Organization. http://www.who.int/healthinfo/ global_burden_disease/estimates/en/index1.html (2015)World Health Organization. http://www.who.int/healthinfo/ global_burden_disease/estimates/en/index1.html (2015)Cuende J. Vascular Age Versus Cardiovascular Risk: Clarifying Concepts. Rev Esp Cardiol. 2016;69(3):243–246. doi: 10.1016/j.rec.2015.10.019Cuende J. Vascular Age Versus Cardiovascular Risk: Clarifying Concepts. Rev Esp Cardiol. 2016;69(3):243–246. doi: 10.1016/j.rec.2015.10.019Lopez-Gonzalez AA, Aguilo A, Frontera M, Bennasar-Veny M, Campos I, Vicente-Herrero T et al. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol. 2015;22(3):389–96. doi: 10.1177/2047487313518479Lopez-Gonzalez AA, Aguilo A, Frontera M, Bennasar-Veny M, Campos I, Vicente-Herrero T et al. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol. 2015;22(3):389–96. doi: 10.1177/2047487313518479Łoboz-Rudnicka M, Jaroch J, Bociąga Z, Kruszyńska E, Ciecierzyńska B, Dziuba M et al. Relationship between vascular age and classic cardiovascular risk factors and arterial stiffness. Cardiol J. 2013;20(4):394–401. doi: 10.5603/CJ.2013.0098Łoboz-Rudnicka M, Jaroch J, Bociąga Z, Kruszyńska E, Ciecierzyńska B, Dziuba M et al. Relationship between vascular age and classic cardiovascular risk factors and arterial stiffness. Cardiol J. 2013;20(4):394–401. doi: 10.5603/CJ.2013.0098Soureti A, Hurling R, Murray P, van Mechelen W, Cobain M. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil. 2010;1(5):519–23. doi:10.1097/HJR. 0b013e328337ccd3Soureti A, Hurling R, Murray P, van Mechelen W, Cobain M. Evaluation of a cardiovascular disease risk assessment tool for the promotion of healthier lifestyles. Eur J Cardiovasc Prev Rehabil. 2010;1(5):519–23. doi:10.1097/HJR. 0b013e328337ccd3Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010;31(19):2351–8. doi:10.1093/eurheartj/ehq205Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010;31(19):2351–8. doi:10.1093/eurheartj/ehq205Cuende JI, Saltijeral A, Estrada V, Pérez De Isla L. Vascular age calculation and equivalent risk factors in HIV-infected patients obtained from the D: A: D risk equation. Eur J Prev Cardiol. 2016;23(17):1903–1908. doi:10.1177/2047487316663546Cuende JI, Saltijeral A, Estrada V, Pérez De Isla L. Vascular age calculation and equivalent risk factors in HIV-infected patients obtained from the D: A: D risk equation. Eur J Prev Cardiol. 2016;23(17):1903–1908. doi:10.1177/2047487316663546Карпов Ю. А., Сорокин Е. В. Влияние комбинированной гипотензивной терапии на риск сердечно-сосудистых осложнений и сосудистый возраст: результаты многоцентрового открытого исследования ADVANT’AGE. Атмосфера. Новости кардиологии. 2015;3:18–26. [Karpov YA, Sorokin EV. Effects of combination antihypertensive therapy on the cardiovascular risk and vascular age: the results of ADVANT’AGE — a multi-center open-label study. Atmosphere. News in Cardiology. 2015;3:18–26. In Russian].Карпов Ю. А., Сорокин Е. В. Влияние комбинированной гипотензивной терапии на риск сердечно-сосудистых осложнений и сосудистый возраст: результаты многоцентрового открытого исследования ADVANT’AGE. Атмосфера. Новости кардиологии. 2015;3:18–26. [Karpov YA, Sorokin EV. Effects of combination antihypertensive therapy on the cardiovascular risk and vascular age: the results of ADVANT’AGE — a multi-center open-label study. Atmosphere. News in Cardiology. 2015;3:18–26. In Russian].Groenewegen KA, den Ruijter HM, Pasterkamp G, Polak JF, Bots ML, Peters SA. Vascular age to determine cardiovascular disease risk: A systematic review of its concepts, definitions, and clinical applications. Eur J Prev Cardiol. 2016;23(3):264–74. doi:10. 1177/2047487314566999Groenewegen KA, den Ruijter HM, Pasterkamp G, Polak JF, Bots ML, Peters SA. Vascular age to determine cardiovascular disease risk: A systematic review of its concepts, definitions, and clinical applications. Eur J Prev Cardiol. 2016;23(3):264–74. doi:10. 1177/2047487314566999Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular disease Prevention in Clinical Practice. Eur Heart J. 2016;37(29):2315–81. doi:10.1093/eurheartj/ehw106Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular disease Prevention in Clinical Practice. Eur Heart J. 2016;37(29):2315–81. doi:10.1093/eurheartj/ehw106Anderson T, Gregoire J, Pearson G, Barry AR, Couture P, Dawes M et al. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263–1282. doi:10. 1016/j.cjca.2016.07.510Anderson T, Gregoire J, Pearson G, Barry AR, Couture P, Dawes M et al. 2016 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263–1282. doi:10. 1016/j.cjca.2016.07.510Stein J, Fraizer M, Aeschlimann S, Nelson-Worel J, McBride PE, Douglas PS. Vascular age: integrating carotid intima-media thickness measurements with global coronary risk assessment. Clin Cardiol. 2004;27(7):388–392.Stein J, Fraizer M, Aeschlimann S, Nelson-Worel J, McBride PE, Douglas PS. Vascular age: integrating carotid intima-media thickness measurements with global coronary risk assessment. Clin Cardiol. 2004;27(7):388–392.D’Agostino RB, Vasan RS, Pencina MJ. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53. doi:10.1161/ CIRCULATIONAHA.107.699579D’Agostino RB, Vasan RS, Pencina MJ. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53. doi:10.1161/ CIRCULATIONAHA.107.699579Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. For the SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE Project. Eur Heart J. 2003;24(11):987–1003.Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. For the SCORE Project Group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE Project. Eur Heart J. 2003;24(11):987–1003.Карпов Ю. А., Сорокин Е. В. Оценка риска осложнений при артериальной гипертонии и сосудистый возраст. Новые инструменты для повышения качества лечения и улучшения взаимопонимания врача и больного. Атмосфера. Новости кардиологии. 2015;2:18–24. [Karpov YA, Sorokin EV. Risk assessment in hypertension and vascular age. New tools for the improvement of the treatment quality and the relationships between the doctor and the patient. Atmosphere. News in Cardiology. 2015;2:18–24. In Russian].Карпов Ю. А., Сорокин Е. В. Оценка риска осложнений при артериальной гипертонии и сосудистый возраст. Новые инструменты для повышения качества лечения и улучшения взаимопонимания врача и больного. Атмосфера. Новости кардиологии. 2015;2:18–24. [Karpov YA, Sorokin EV. Risk assessment in hypertension and vascular age. New tools for the improvement of the treatment quality and the relationships between the doctor and the patient. Atmosphere. News in Cardiology. 2015;2:18–24. In Russian].Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet. 2005;366 (948):895–906. doi:10.1016/S0140–6736(05)67185–1Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet. 2005;366 (948):895–906. doi:10.1016/S0140–6736(05)67185–1Prieto-Merino D, Dobson J, Gupta AK, Chang CL, Sever PS, Dahlöf B et al. ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. J Hum Hypertens. 2013;27(8):492–496. doi:10.1038/jhh.2013.3Prieto-Merino D, Dobson J, Gupta AK, Chang CL, Sever PS, Dahlöf B et al. ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. J Hum Hypertens. 2013;27(8):492–496. doi:10.1038/jhh.2013.3Кобалава Ж. Д., Котовская Ю. В., Маркова М. А., Алам А., Доронина А. Ю. Сосудистое старение и артериальная гипертония // Кобалава Ж. Д., Котовская Ю. В. Артериальная гипертония в ХХI веке: достижения, проблемы, перспективы. М.: Бионика Медиа, 2015:91–113. [Kobalava ZD, Kotovskaya YV, Markova MA, Alam A, Doronina AY. Vascular ageing and arterial hypertension//Kobalava ZD, Kotovskaya YV. Arterial hypertension in the XXI century: achievements, problems and perspectives. Moscow: Bionica Media, 2015:91–113. In Russian].Кобалава Ж. Д., Котовская Ю. В., Маркова М. А., Алам А., Доронина А. Ю. Сосудистое старение и артериальная гипертония // Кобалава Ж. Д., Котовская Ю. В. Артериальная гипертония в ХХI веке: достижения, проблемы, перспективы. М.: Бионика Медиа, 2015:91–113. [Kobalava ZD, Kotovskaya YV, Markova MA, Alam A, Doronina AY. Vascular ageing and arterial hypertension//Kobalava ZD, Kotovskaya YV. Arterial hypertension in the XXI century: achievements, problems and perspectives. Moscow: Bionica Media, 2015:91–113. In Russian].Котовская Ю. В., Троицкая Е. А., Кобалава Ж. Д. Преждевременное старение сосудистого русла: роль артериальной ригидности и возможности медикаментозной терапии с использованием периндоприла А. Consilium medicum. 2013;15(10):101–107 [Kotovskaya YV, Troitskaya EA, Koba-lava ZD. Early vascular ageing: role of arterial stiffness and treatment options with Perindopril A. Consilium medicum. 2013;15(10):101–107. In Russian].Котовская Ю. В., Троицкая Е. А., Кобалава Ж. Д. Преждевременное старение сосудистого русла: роль артериальной ригидности и возможности медикаментозной терапии с использованием периндоприла А. Consilium medicum. 2013;15(10):101–107 [Kotovskaya YV, Troitskaya EA, Koba-lava ZD. Early vascular ageing: role of arterial stiffness and treatment options with Perindopril A. Consilium medicum. 2013;15(10):101–107. In Russian].O’Rourke MF, Safar ME, Dzau V. The Cardiovascular Continuum extended: aging effects on the aorta and micro-vasculature. Vasc Med. 2010;15(6):461–468. doi:10.1177/ 1358863X10382946O’Rourke MF, Safar ME, Dzau V. The Cardiovascular Continuum extended: aging effects on the aorta and micro-vasculature. Vasc Med. 2010;15(6):461–468. doi:10.1177/ 1358863X10382946Nilsson P. Vascular age: how can it be determined? What are it’s clinical applications? Medicographia. 2015;37:454–460.Nilsson P. Vascular age: how can it be determined? What are it’s clinical applications? Medicographia. 2015;37:454–460.O’Rourke M. Mechanical principles in arterial disease. Hypertension. 1995;26(1):2–9. doi:10.1161/01.HYP.26.1.2O’Rourke M. Mechanical principles in arterial disease. Hypertension. 1995;26(1):2–9. doi:10.1161/01.HYP.26.1.2Laurent S. Defining vascular aging and cardiovascular risk. J Hypertens 2012;30(Suppl 1):S3-S8. doi:10.1097/HJH. 0b013e328353e501Laurent S. Defining vascular aging and cardiovascular risk. J Hypertens 2012;30(Suppl 1):S3-S8. doi:10.1097/HJH. 0b013e328353e501Laurent S, Marais L, Boutouyrie P. The Noninvasive assessment of vascular aging. Can J Cardiol. 2016;32(5):669–79. doi:10.1016/j.cjca.2016.01.039Laurent S, Marais L, Boutouyrie P. The Noninvasive assessment of vascular aging. Can J Cardiol. 2016;32(5):669–79. doi:10.1016/j.cjca.2016.01.039Reece AS, Hulse GK. Impact of lifetime opioid exposure on arterial stiffness and vascular age: cross-sectional and longitudinal studies in men and women. Br Med J. 2014;4: e004521. doi:10.1136/bmjopen-2013–004521Reece AS, Hulse GK. Impact of lifetime opioid exposure on arterial stiffness and vascular age: cross-sectional and longitudinal studies in men and women. Br Med J. 2014;4: e004521. doi:10.1136/bmjopen-2013–004521Takazawa K, Tanaka N, Fujita M, Matsuoka O, Saiki T, Aikawa M et al. Assessment of vasoactive agents and vascular aging by the second derivative of photoplethysmogram waveform. Hypertension. 1998;32(2):365–370.Takazawa K, Tanaka N, Fujita M, Matsuoka O, Saiki T, Aikawa M et al. Assessment of vasoactive agents and vascular aging by the second derivative of photoplethysmogram waveform. Hypertension. 1998;32(2):365–370.Парфенов А. С. Ранняя диагностика сердечно-сосудистых заболеваний с использованием аппаратно-программного комплекса «Ангиоскан-01». Поликлиника. 2012; 2:1–6. [Parfenov AS. Early diagnostics of cardio-vascular diseases with the new device ANGIOSCAN-01. Polyclinics. 2012;2:1–6. In Russian].Парфенов А. С. Ранняя диагностика сердечно-сосудистых заболеваний с использованием аппаратно-программного комплекса «Ангиоскан-01». Поликлиника. 2012; 2:1–6. [Parfenov AS. Early diagnostics of cardio-vascular diseases with the new device ANGIOSCAN-01. Polyclinics. 2012;2:1–6. In Russian].de Andrade CR, Silva EL, da Matta MF, Castier MB, Rosa ML, Gomes MB. Vascular or chronological age: which is the better marker to estimate the cardiovascular risk in patients with type 1 diabetes? Acta Diabetol. 2016;53(6):925–933. doi:10. 1007/s00592–016–0891–8de Andrade CR, Silva EL, da Matta MF, Castier MB, Rosa ML, Gomes MB. Vascular or chronological age: which is the better marker to estimate the cardiovascular risk in patients with type 1 diabetes? Acta Diabetol. 2016;53(6):925–933. doi:10. 1007/s00592–016–0891–8McClelland RL, Nasir K, Budoff M, Blumenthal RS, Kronmal RA. Arterial age as a function of coronary artery calcium from the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Cardiol. 2009;103(1):59–63. doi:10.1016/j.amjcard.2008.08.031McClelland RL, Nasir K, Budoff M, Blumenthal RS, Kronmal RA. Arterial age as a function of coronary artery calcium from the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Cardiol. 2009;103(1):59–63. doi:10.1016/j.amjcard.2008.08.031Bonner C, Jansen J, Newell BR, Irwig L, Glasziou P, Doust J et al. I don’t believe it, but I’d better do something about it: patient experiences of online heart age risk calculators. J Med Internet Res. 2014;16: e120. doi:10.2196/jmir.3190Bonner C, Jansen J, Newell BR, Irwig L, Glasziou P, Doust J et al. I don’t believe it, but I’d better do something about it: patient experiences of online heart age risk calculators. J Med Internet Res. 2014;16: e120. doi:10.2196/jmir.3190Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the check-up study: a randomized controlled trial. Arch Intern Med. 2007;167(21):2296–2303. doi:10.1001/archinte.167.21.2296Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L et al. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: the check-up study: a randomized controlled trial. Arch Intern Med. 2007;167(21):2296–2303. doi:10.1001/archinte.167.21.2296Zacarias A, Vaquero C, Narvaez F, Nolla JM, Gonzalez-Gay MA, Gonzalez-Juanatey et al. Utility of relative cardiovascular risk score scales and vascular age predictors in patients with rheumatoid arthritis UNDER 50 YEARS of age. 2016 ACR/ARHP Annual Meeting Archives: 170, abstract 1464.Zacarias A, Vaquero C, Narvaez F, Nolla JM, Gonzalez-Gay MA, Gonzalez-Juanatey et al. Utility of relative cardiovascular risk score scales and vascular age predictors in patients with rheumatoid arthritis UNDER 50 YEARS of age. 2016 ACR/ARHP Annual Meeting Archives: 170, abstract 1464.Clavreul N. Tailored-treatment approach for the management of hypertension. Medicographia. 2015;37:440–448.Clavreul N. Tailored-treatment approach for the management of hypertension. Medicographia. 2015;37:440–448.Asmar RG, London GM, O’Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38(4):922–926.Asmar RG, London GM, O’Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38(4):922–926.Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–1225. doi:10.1161/ CIRCULATIONAHA.105.595496Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–1225. doi:10.1161/ CIRCULATIONAHA.105.595496Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788.Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788.Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G et al. ACE inhibition with perindopril andendothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73(1):237–246. doi:10. 1016/j.cardiores.2006.10.021Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G et al. ACE inhibition with perindopril andendothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res. 2007;73(1):237–246. doi:10. 1016/j.cardiores.2006.10.021

The authors declare that there are no conflicts of interest present.